Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
HKMA Intervenes to Defend the Hong Kong Dollar Peg
27:02 - Hong Kong’s de facto central bank stepped in for the first time in more than four months to prevent the city’s currency from breaking out of the strong end of its pegged range against the U.S. dollar. Bloomberg's David Ingles reports on "First Up." (Source: Bloomberg)
  • The Top Three Stocks to Watch in Asia Today
  • Tech Opportunities: Bloomberg West (Full Show 9/01)
  • Stocks Extend Declines: What'd You Miss? (Full Show 9/01)